REDD1 Activates a ROS-Generating Feedback Loop in the Retina of Diabetic Mice

William P. Miller,1 Allyson L. Toro,1 Alistair J. Barber,1,2 and Michael D. Dennis1,2

1Department of Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, Pennsylvania, United States
2Department of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania, United States

PURPOSE. The present study was designed to evaluate the role of the stress response protein REDD1 in diabetes-induced oxidative stress and retinal pathology.

METHODS. Wild-type and REDD1-deficient mice were administered streptozotocin to induce diabetes. Some mice received the antioxidant N-acetylcysteine (NAC). Visual function was assessed by virtual optometry. Retinas were analyzed by Western blotting. Reactive oxygen species (ROS) were assessed by 2,7-dichlorofluoroscein. Similar analyses were performed on R28 retinal cells in culture exposed to hyperglycemic conditions, NAC, and/or the exogenous ROS source hydrogen peroxide.

RESULTS. In the retina of diabetic mice, REDD1 expression and ROS were increased. In cells in culture, hyperglycemic conditions enhanced REDD1 expression, ROS levels, and the mitochondrial membrane potential. However, similar effects were not observed in the retina of diabetic mice or cells lacking REDD1. In the retina of diabetic mice and cells exposed to hyperglycemic conditions, NAC normalized ROS and prevented an increase in REDD1 expression. Diabetic mice receiving NAC also exhibited improved contrast sensitivity as compared to diabetic controls. Hydrogen peroxide addition to culture medium increased REDD1 expression and attenuated Akt/GSK3 phosphorylation in a REDD1-dependent manner. In REDD1-deficient cells exposed to hyperglycemic conditions, expression of a dominant negative Akt or constitutively active GSK3 increased the mitochondrial membrane potential and promoted ROS.

CONCLUSIONS. The findings provide new insight into the mechanism whereby diabetes-induced hyperglycemia causes oxidative stress and visual dysfunction. Specifically, hyperglycemia-induced REDD1 activates a ROS-generating feedback loop that includes Akt/GSK3. Thus, therapeutic approaches targeting REDD1 expression and ROS may be beneficial for preventing diabetes-induced visual dysfunction.

Keywords: antioxidants, diabetes, oxidative stress, retina, vision
(PP2A) inhibits Akt kinase activity by dephosphorylation of the kinase. This reduction in Akt activity leads to increased GSK3β-dependent phosphorylation of VDAC, reduced mitochondrial association with HK, and increased ROS production.

The stress response protein regulated in development and DNA damage 1 (REDD1) promotes association of PP2A with Akt, leading to site-specific dephosphorylation of the kinase and subsequent reduction in Akt-mediated phosphorylation of GSK3β. Thus, we speculated that REDD1 expression may be a critical element in the feedback loop that increases ROS production in response to hyperglycemic conditions. Since its discovery, REDD1 has been linked to the regulation of ROS.17–20 Our laboratory recently demonstrated that REDD1 expression is increased in the retina of diabetic mice by hyperglycemia,21 coincident with attenuated Akt kinase activity and increased retinal cell death.22 In the retina of diabetic mice lacking REDD1, Akt activity remains elevated and cell death is similar to that observed in nondiabetic controls.22

In fact, genetic ablation of REDD1 prevents electroretinogram defects or visual threshold deficits in diabetic mice.22 Similarly, REDD1 has also been linked to the development of ischemic proliferative retinopathy.23 Remarkably, the DEGS1 study demonstrates that intravitreal injection of a siRNA targeting the REDD1 mRNA is more effective than laser photocoagulation in improving visual acuity in patients with diabetic macular edema.24 Improved vision in patients treated with a siRNA targeting the REDD1 mRNA occurred in the absence of altered anatomical features or fluorescein leakage, suggesting a mechanism independent of changes in vascular permeability. In the present study, we investigated the mechanism responsible for the protective effects of REDD1 deletion on diabetes-induced visual dysfunction.

**METHODS**

**Animals**

Male C57Bl6/N mice (Charles River, Wilmington, MA, USA) and wild-type/REDD1 knockout B6;129 mice25 were administered either 50 mg/kg streptozotocin (STZ) or sodium citrate buffer for 5 consecutive days to induce diabetes. Diabetic phenotype was assessed with fasting blood glucose levels >250 mg/dL. Approximately 2 g/kg per day β-acetylated-cysteine (NAC) was administered via drinking water. All procedures were approved by the Penn State College of Medicine Institutional Animal Care and Use Committee.

**Cell Culture**

CRISPR/Cas9 genome editing to generate a stable R28 cell line deficient in REDD1 was previously described.22 REDD1 knockout mouse embryonic fibroblasts (MEF) were provided by L. E. Ellisen (Harvard Medical School, Boston, MA, USA). Cells were cultured on plates (CellBIND; Corning, Corning, NY, USA) with Dulbecco’s modified Eagle’s medium (DMEM) containing 5 mM glucose and 10% fetal bovine serum (FBS). R28 medium was supplemented with 1X MEM nonessential amino acids, 1X MEM vitamin solution, and 0.14% gentamycin. MEF medium was supplemented with 1% penicillin/streptomycin. For studies on the effects of hyperglycemic conditions, cell culture medium contained either 30 mM glucose or 5 mM glucose with 25 mM mannitol as an osmotic control. Where indicated, cells were cultured in medium without FBS for 24 hours. In specific studies, culture medium was supplemented with 100 nM insulin (Lilly, Indianapolis, IN, USA), 10 mM NAC (Sigma-Aldrich Corp., St. Louis, MO, USA), or 1 mM hydrogen peroxide. Cells were transfected with pCMV5 vector; pCMV-HA-REDD1 (human), pCMV-HA-GSK3-59A (no. 14754; Addgene, Watertown, MA, USA) or pCMV-HA-AKT-K147M (no. 16243; Addgene) plasmids using a reagent (Lipofectamine 2000; Life Technologies, Carlsbad, CA, USA). To evaluate mitochondrial membrane potential, cells were transferred to Opti-MEM reduced-serum media lacking phenol red and stained with 1 μg/mL dye (JC-1; Life Technologies).

**ROS Measurement**

Eyes were harvested, embedded in OCT, and flash frozen. Cryosections (10 μm) were fixed with 2% paraformaldehyde in PBS (pH 7.4). Cryosections were stained with 1.6 μM Hoechst and 10 μM 2,7-dichloroﬂuorescein (DCF). Sections were imaged using a confocal laser microscope (l.ex = 504 nm) (Leica SP8; Leica, Wetzlar, Germany). Alternatively, retinas were also homogenized in lysis buffer as previously described.22 Lysates were centrifuged at 1500g for 3 minutes, and the supernatant was exposed to 10 μM DCF. Fluorescence was measured using a plate reader (Spectra Max M5; Molecular Devices, San Jose, CA, USA) (ex/em = 504/529 nm). ROS were assessed in cells in culture using a DCF diacetate (DCFDA) assay kit (DCFDA Cellular ROS Detection Assay kit; Abcam, Cambridge, United Kingdom). To assess mitochondrial superoxide, cells were cultured on 35 mm poly-d-lysine-coated glass-bottom culture dishes with No. 1.5 coverslip (MatTek Corp., Ashland, MA, USA) and exposed to 5 μM MitoSOX (Thermo Fisher Scientific, Waltham, MA, USA) prepared in Hank’s buffered salt solution supplemented with 1.3 mM calcium and 0.9 mM magnesium.

**Cell Death ELISA**

Cells or retinas were homogenized in lysis buffer and relative cell death was evaluated using an ELISA kit (Cell Death Detection ELISA Kit; Roche, Basel, Switzerland) as previously described.22

**Western Blot Analysis**

Retinas were flash frozen in liquid nitrogen and homogenized in 250 μL of lysis buffer as previously described.22 Cell lysates and retinal homogenates were fractionated using 4%–20% gels (Criterion Precast; Bio-Rad Laboratories, Hercules, CA, USA). Proteins were transferred to a polyvinylidene fluoride membrane, reversibly stained to assess protein loading ( Pierce, Waltham, MA, USA), blocked in 5% milk in Tris-buffered saline Tween 20, and evaluated with the appropriate antibodies (Table).

**RNA Isolation and Quantitative PCR (qPCR)**

Total RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA, USA). RNA (1 μg) was reverse transcribed using a reverse transcription kit (High Capacity cDNA Reverse Transcription Kit; Applied Biosystems, Foster City, CA, USA) and subjected to quantitative real-time PCR (Q12K Flex Real-Time PCR System; Applied Biosystems) using a PCR kit (QuantiTect SYBR Green Master Mix; Qiagen, Hilden, Germany) as previously described.25 Primers for REDD1 were as follows: 5′-TCGGA GAGGCAATCGCT-3′ and 5′-GAAGAGGAAGAGGAAGAAGGAACGA-3′. Mean cycle threshold (Ct) values for REDD1 and GAPDH were determined for control and experimental samples.

Changes in REDD1 mRNA expression were normalized to GAPDH mRNA expression using the 2^ΔΔCt calculation as previously described.26
protein expression and cell death (Fig. 1C–1D). TUNEL-supplementation prevented diabetes-induced retinal REDD1 increased in the retina of diabetic mice. However, NAC expression (Fig. 1C) and cell death (Fig. 1D) were also increased in diabetic wild-type mice, but not detectable in REDD1 knockout mice (Fig. 2B). In the retina of wild-type diabetic mice, DCF fluorescence was increased as compared to nondiabetic controls (Fig. 2C–2D). In nondiabetic REDD1-deficient mice, DCF fluorescence was similar to that observed in nondiabetic wild-type mice. In contrast to the effect of diabetes in wild-type mice, ROS levels were similar in diabetic and nondiabetic REDD1-knockout mice.

**Behavioral Assessment of Visual Thresholds**

A virtual optomotor system (OptoMotry; Cerebral Mechanics, Irvine, CA, USA) was used to assess visual function in mice as previously described.27 Spatial frequency (SF) and contrast sensitivity (CS) thresholds were identified as the highest values that elicited a reflexive head movement. CS was evaluated at an SF of 0.092 cycles/deg. SF was assessed at 100% contrast. CS was expressed as an inverse percentage to make data interpretation more intuitive.

**Statistical Analysis**

Data are expressed as mean ± SEM. Data were analyzed overall with ANOVA, and trend test and pairwise comparisons were conducted with the Tukey test for multiple comparisons. A t-test was used to compare mean differences between 5 and 30 mM glucose concentrations (see Fig. 3). Significance was defined as P < 0.05 for all analyses.

**RESULTS**

**NAC Supplementation Attenuates Retinal ROS and REDD1 Expression in a Model of Type 1 Diabetes**

To evaluate the role of diabetes-induced oxidative stress in retinal cell death and visual dysfunction, STZ-diabetic mice were administered NAC over a 4-week period of diabetes. NAC is an antioxidant and glutathione precursor, and supplementation has been previously shown to have beneficial effects on DR pathology.28,29 To evaluate oxidative stress, retinal cryosections were exposed to the fluorescent ROS indicator DCF. Consistent with the previous report,30 diabetes increased retinal ROS as assessed by DCF fluorescence (Fig. 1A, 1B). Quantitative assessment of ROS in retinal tissue lysates demonstrated that NAC reduced ROS levels in both diabetic and nondiabetic mice as compared to vehicle controls (Fig. 1B). In fact, DCF fluorescence was similar in the retina of diabetic mice treated with NAC and nondiabetic controls. Consistent with our previous studies,31,32 REDD1 protein expression (Fig. 1C) and cell death (Fig. 1D) were also increased in the retina of diabetic mice. However, NAC supplementation prevented diabetes-induced retinal REDD1 protein expression and cell death (Fig. 1C–1D). TUNEL-positive nuclei and cells containing positive immunoreactivity for the active form of caspase 3 have been observed in the retina of diabetic rodents during the first 4 weeks of hyperglycemia.31,32 The position of cells containing activated caspase 3 was consistent with bipolar neurons, amacrine cells, and retinal ganglion cells, and their colocalization with the NeuN and tyrosine hydroxylase antigens further supports that these cells were neuronal.33

**NAC Supplementation Improves Contrast Sensitivity in a Model of Type 1 Diabetes**

To determine if there was a functional effect of NAC supplementation on vision, we performed behavioral optometry. Consistent with our previous report,27 visual acuity (Fig. 1E) and contrast sensitivity (Fig. 1F) deficits were observed after 4 weeks of diabetes. NAC supplementation had no effect on visual acuity. However, contrast sensitivity was improved in diabetic mice receiving NAC as compared to diabetic controls, such that there was no difference between diabetic and nondiabetic mice receiving NAC. While there was a trend toward lower blood glucose levels in mice treated with NAC for 4 weeks (P = 0.055), blood glucose levels were similar in diabetic mice with and without NAC supplementation (Fig. 1G).

**REDD1 Deletion Is Sufficient to Prevent Diabetes-Induced ROS in Retina**

To evaluate the role of REDD1 in diabetes-induced oxidative stress, mice with a germline disruption of REDD1 were administered STZ. After 4 weeks of diabetes, wild-type and REDD1 knockout mice exhibited a similar increase in postprandial blood glucose concentrations (Fig. 2A). REDD1 protein expression was increased in retinal lysates from diabetic wild-type mice, but not detectable in REDD1 knockout mice (Fig. 2B). In the retina of wild-type diabetic mice, DCF fluorescence was increased as compared to nondiabetic controls (Fig. 2C–2D). In nondiabetic REDD1-deficient mice, DCF fluorescence was similar to that observed in nondiabetic wild-type mice. In contrast to the effect of diabetes in wild-type mice, ROS levels were similar in diabetic and nondiabetic REDD1-knockout mice.

**Hyperglycemic Conditions Increase ROS, REDD1 Expression, and Cell Death in R28 Cells in Culture**

To further explore hyperglycemia-induced ROS, R28 retinal cells were maintained in culture medium containing 5 mM glucose and then exposed to medium containing 30 mM glucose. R28 cells are an immortalized rat retinal cell line derived from a mixed population of cells that express both neuronal and glial antigens.34 Their generic nature and the ability to culture large numbers of R28 cells make them particularly useful to study the molecular events associated with exposure to hyperglycemic conditions. Cells were stained with DCFDA, which can passively diffuse into cells and particularly useful to study the molecular events associated with exposure to hyperglycemic conditions. Cells were stained with DCFDA, which can passively diffuse into cells and become hydrolyzed by cellular esterases to form DCF. In R28 cells exposed to culture medium containing 30 mM glucose, DCF fluorescence was enhanced (Fig. 3A, 3B). In contrast, a similar effect on DCF fluorescence was not observed in cells exposed to culture medium containing 5 mM glucose and 25 mM mannitol as an osmotic control (Fig. 3A). In a previous study, we demonstrated that REDD1 expression was necessary for hyperglycemic conditions to promote cell death.22 In support of that study, exposure to culture medium containing 30 mM glucose increased REDD1 protein expression (Fig. 3C).
and increased cell death as assessed by caspase 3 cleavage (Fig. 3D) and DNA fragmentation (Fig. 3E).

**REDD1 Deletion Attenuates Glucose-Induced ROS in R28 Cells in Culture**

To evaluate the role of REDD1 in hyperglycemia-induced ROS production, wild-type and REDD1-deficient R28 cells were exposed to hyperglycemic conditions. REDD1 mRNA abundance was increased in wild-type cells exposed to hyperglycemic conditions but was not detected upon genomic disruption via CRISPR (Fig. 3F). Unlike wild-type cells, REDD1-deficient R28 cells did not exhibit an increase in DCF fluorescence upon exposure to hyperglycemic conditions (Fig. 3G, 3H). In agreement with this finding, REDD1 deletion also prevented hyperglycemia-induced ROS in MEF in culture (Fig. 3I). To further investigate the mechanism whereby REDD1 contributes to increased ROS levels, we evaluated mitochondrial superoxide in live cells. R28 cells exposed to hyperglycemic conditions exhibited an increase in mitochondrial superoxide,
whereas the effect was prevented by REDD1 deletion (Fig. 3J).

Due to the importance of \( \Delta \Psi_m \) in ROS production,\(^1\) we also assessed the impact of hyperglycemic conditions on mitochondrial membrane potential using JC-1 dye. In wild-type R28 cells, exposure to hyperglycemic conditions increased the red fluorescent signal derived from JC-1 aggregates, implying an increase in the mitochondrial membrane potential (Fig. 3K). In REDD1-deficient cells, the ratio of JC-1 aggregate/monomer was similar to that observed in wild-type cells cultured in medium containing 5 mM glucose and, unlike in wild-type cells, did not increase upon exposure to hyperglycemic conditions (Fig. 3L).

**NAC Prevents Glucose-Induced ROS, REDD1 Expression, and Cell Death in R28 Cells in Culture**

In addition to hyperglycemic culture conditions, REDD1 expression is also induced by serum deprivation.\(^3\) We recently demonstrated that insulin addition to serum-deficient culture medium prevented an increase in REDD1 protein expression in R28 cells.\(^2\) To further evaluate the relationship between ROS, REDD1 expression, and cell death, R28 cells were exposed to serum-deficient culture medium containing 5 mM glucose and, unlike in wild-type cells, did not increase upon exposure to hyperglycemic conditions (Fig. 3L).

**ROS Promotes REDD1 Expression to Attenuate Akt/GSK3 Phosphorylation in R28 Cells in Culture**

Because increased ROS levels were necessary for hyperglycemia-induced REDD1, we wanted to determine if enhanced ROS levels were sufficient to promote REDD1 expression. In wild-type R28 cells, addition of the exogenous ROS source H\(_2\)O\(_2\) to culture medium increased the expression of REDD1 protein (Fig. 5A) and mRNA (Fig. 5B) expression. In addition, H\(_2\)O\(_2\) attenuated phosphorylation of Akt at Thr308 (Fig. 5C) and GSK3\(\beta\) at Ser9 (Fig. 5D). In contrast, cells deficient in REDD1 did not exhibit attenuated phosphorylation of Akt or GSK3\(\beta\) upon exposure to H\(_2\)O\(_2\).
**Figure 3.** REDD1 deletion is sufficient to prevent hyperglycemia-induced ROS. R28 retinal cells were maintained in DMEM containing 5 mmol/L glucose and supplemented with 10% FBS. (A) Cells were exposed to medium containing 5 mmol/L glucose, 30 mmol/L glucose, or 5 mmol/L glucose plus 25 mmol/L mannitol as an osmotic control for 24 hours. ROS were visualized with DCFDA. DCF fluorescence and bright-field (BF) images are shown. (B) DCF fluorescent intensity per well was quantified using a plate reader. (C, D) REDD1, caspase-3 cleavage, and tubulin protein expression were assessed by Western blotting. Protein molecular mass (kDa) is indicated at the right of blots. (E) Relative cell death was assessed by ELISA of cytoplasmic nucleosomes. R28 WT and REDD1 KO (sgREDD1) cells were maintained in DMEM containing 5 mmol/L glucose supplemented with 10% FBS (F–H, J–L). Cells were exposed to medium containing 5 mmol/L or 30 mmol/L glucose for 24 hours. (F) REDD1 mRNA expression was assessed by qPCR. (G) ROS were visualized with DCFDA, and DCF fluorescent intensity was quantified (H). (I) ROS levels were similarly evaluated in REDD1+/+ and REDD1−/− MEF. REDD1 and tubulin protein expression were assessed by Western blotting. Protein loading was evaluated by reversible protein stain. (J) Mitochondrial superoxide was assessed by MitoSOX stain. (K, L) Mitochondrial membrane potential was evaluated with JC-1 dye. JC-1 aggregates and monomers were quantified. Results are representative for three experiments. Within each experiment, 3 to 10 independent samples were analyzed. Values are means ± SEM. *P < 0.05 versus Veh; #P < 0.05 versus WT. nd, not detected.
We next investigated the mechanism responsible for the reduction in hyperglycemia-induced ROS upon REDD1 deletion. In REDD1-deficient R28 cells exposed to hyperglycemic conditions, restoring REDD1 expression was sufficient to promote ROS levels (Fig. 6A, 6B). Similarly, expression of either constitutively active GSK3βS9A (caGSK3) or dominant negative AktK147M (dnAkt) promoted ROS levels in REDD1-deficient cells as compared to an empty vector. REDD1, caGSK3, or dnAkt expression were also sufficient to increase the mitochondrial membrane potential in REDD1-deficient R28 cells exposed to hyperglycemic conditions (Fig. 6C). Overall, these findings support a model wherein REDD1 activates a ROS-generating feedback loop in response to hyperglycemic conditions (Fig. 6D).

**DISCUSSION**

The current study investigated the role of REDD1- and diabetes-induced oxidative stress in retinal apoptosis and visual dysfunction. In a recent study, we demonstrated that REDD1 protein expression is increased in the retina of diabetic mice, and deletion of REDD1 is sufficient to prevent diabetes-induced retinal cell death, electroretinogram (ERG) defects, and impaired visual thresholds. The protective effect of REDD1 deletion on diabetes-induced deficits is consistent with functional expression of REDD1 in the inner retina. Herein, we provide new insight into the mechanism responsible for the protective effect of REDD1 deletion in the retina of diabetic mice. Overall, the findings support a model whereby diabetes-induced hyperglycemia promotes REDD1 expression in a manner that activates a ROS-generating feedback loop, leading to increased retinal cell death and visual dysfunction (Fig. 6D).
In the present study, the functional consequence of diabetes-induced oxidative stress in the retina was evaluated by treating mice with the antioxidant NAC. NAC is a precursor of the amino acid cysteine, which is required for synthesis of the tripeptide glutathione (GSH). Reduced GSH is the most abundant antioxidant in human cells and plays a critical role in cellular redox signaling. In diabetic patients, GSH synthesis is diminished due to limited cysteine availability. In fact, cysteine and glycine supplementation to restore GSH synthesis normalizes elevated plasma markers of oxidative stress and lipid peroxides in diabetic patients. In this study, NAC supplementation normalized ROS levels in the retina of diabetic mice. In addition, NAC reduced REDD1 protein expression and markers of cell death in the retina of diabetic mice. NAC supplementation also improved visual function in diabetic mice as assessed by measurement of the optomotor response. We recently reported that REDD1 deletion prevents the development of visual deficits in STZ-diabetic mice. Whereas wild-type diabetic mice exhibit deficits in both visual acuity and contrast sensitivity, neither of these measures of functional vision are reduced in diabetic REDD1 knockout mice as compared to nondiabetic REDD1 knockout mice. Herein, NAC supplementation prevented increased REDD1 expression in the retina of STZ-diabetic mice. Similar to the principal effect of REDD1 deletion in the previous study, NAC supplementation also protected contrast sensitivity.

While it is well-established that DR is associated with decline in contrast sensitivity, diabetic patients without clinical signs of retinopathy also exhibit a reduction in contrast sensitivity. Contrast sensitivity is particularly important element of visual function in low light conditions, when differences in luminance make distinguishing borders and details more difficult. Notably, contrast sensitivity is principally associated with inner retinal information processing, as compared to the outer retina and photoreceptor function. An important caveat is that the effects of NAC on the retina may not be direct but rather secondary to improved glucose homoeostasis. Consistent with the previous report, STZ-diabetic diabetic mice receiving NAC in this study did not exhibit a significant reduction in blood glucose levels. Regardless, improved visual function in diabetic mice receiving NAC is not likely due exclusively to events restricted to the retina.

The findings here provide what we believe to be new evidence that REDD1 plays an important role in oxidative stress in the retina of diabetic mice. Specifically, REDD1 deletion prevented a diabetes-induced increase in retinal DCF fluorescence. ROS levels were similar in wild-type and REDD1-deficient R28 and MEF cells when cultured in medium containing 5 mM glucose. Wild-type cells exhibited increased REDD1 expression and enhanced ROS levels upon exposure to medium containing 30 mM glucose; however, REDD1-deficient cells did not. We previously demonstrated that hyperglycemia promotes REDD1 protein expression in the retina of diabetic mice. In diabetic mice treated with phloridzin to promote renal glucosuria and normalize blood glucose levels, retinal REDD1 expression was similar to that observed in nondiabetic controls. In the present study, ROS scavenging by NAC prevented increased REDD1 expression in the retina of diabetic mice and in cells in culture exposed to hyperglycemic conditions. Furthermore, increasing cellular ROS via an exogenous source (i.e., H2O2 addition to culture medium) was sufficient to enhance REDD1 protein expression. Thus, REDD1 is not the only important regulator of cellular ROS in response to hyperglycemic conditions; ROS also regulate REDD1 expression.

Ellisen et al. first demonstrated that REDD1 promotes ROS levels in TP63-null fibroblasts. In that same year, Shoshani et al. found that REDD1 expression was dramatically upregulated in ischemic cells of neuronal origin and promoted cell death in neuron-like PC12 cells by increasing sensitivity to oxidative stress. Consistent with the findings here, cells lacking REDD1 cultured in medium containing 25 mM glucose exhibit lower ROS levels as compared to wild-type cells. Reduced ROS in REDD1-deficient cells is linked to an effect on mitochondria and is due, at least in part, to enhanced antioxidant activity of thioredoxin. Thioredoxin is a major regulator of cellular redox signaling and plays a critical role in protecting cells from oxidative stress. Qiao et al. demonstrated that REDD1 forms a stress-induced complex with thioredoxin-interacting protein (TXNIP). TXNIP inhibits thioredoxin antioxidant function by binding to its redox-active cysteine residues. In both REDD1−/− and TXNIP−/− cells, thioredoxin activity is elevated and ROS levels are reduced. In REDD1−/− cells, increased TXNIP expression was insufficient to increase ROS levels. With regards to DR, TXNIP expression is upregulated in the retina of diabetic mice, and TXNIP knockdown is sufficient to reduce diabetes-induced retinal pathology. In addition to binding to TXNIP, REDD1 also interacts with phosphatase 2A (PP2A) and Akt. Retinal Akt kinase activity is attenuated as early as 4 weeks after the onset of diabetes and is associated with a decrease in REDD1 protein expression. In fact, REDD1 deletion prevents the suppressive effect of diabetes on Akt activity in retinal lysates. In R28 retinal cells exposed to hyperglycemic conditions, enhanced REDD1 protein expression mediates a reduction in Akt phosphorylation. Enhanced REDD1 expression is also associated with attenuated phosphorylation of GSK3β. In the present study, H2O2 addition to culture medium failed to suppress Akt or GSK3β phosphorylation in REDD1-deficient cells. Overall, the...
findings here are consistent with a model wherein hyperglycemia-induced REDD1 expression inhibits Akt and activates GSK3. In retinal cells exposed to hyperglycemic condition, REDD1 protein expression, mitochondrial membrane potential, and ROS levels were increased. REDD1 deletion prevented the increase in mitochondrial membrane potential and normalized ROS levels upon exposure to hyperglycemic conditions. Moreover, expression of a dominant negative variant of Akt or a constitutively active variant of GSK3 increased the mitochondrial membrane potential and ROS levels in the absence of REDD1. This supports a model proposed by Giacco et al.8 wherein hyperglycemic conditions activate a multicomponent feedback loop involving PP2A, Akt, and GSK3 to maintain a high mitochondrial membrane potential and promote mitochondrial ROS production. Thus, REDD1 expression reduces the antioxidant capacity of cells by promoting TXNIP-dependent inhibition of thioredoxin and enhances mitochondrial ROS production via PP2A-dependent repression of Akt.

The findings here support the conclusion that hyperglycemia-induced ROS promote REDD1 expression to activate a ROS-generating feedback loop in response to hyperglycemia. ns, nonspecific.

Acknowledgments

The authors thank Elena Feinstein (Quark Pharmaceuticals) for permission to use the REDD1 knockout mice and Leif Ellisen (Harvard Medical School) for providing REDD1 wild-type and REDD1-knockout MEF. We also gratefully acknowledge Leonard Jefferson and Scot Kimball (Penn State College of Medicine) for critically evaluating the manuscript. Parts of this study were presented in abstract form at the 78th Scientific Session of the American Diabetes Association, Orlando, Florida, United States, June 2018.

Supported by the American Diabetes Association Pathway to Stop Diabetes Grant 1-14-INI-04 and National Eye Institute Grant EY023612.

Disclosure: W.P. Miller, None; A.L. Toro, None; A.J. Barber, None; M.D. Dennis, None

References

1. Lind M, Oden A, Fahlen M, Eliasson B. The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables. PLoS One. 2009;4:e4412.
REDD1 Promotes Oxidative Stress in Retina

2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1995;329:977–986.

3. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes*. 2005;54:1615–1625.

4. Kowlu RA, Kern TS, Engerman RL, Armstrong D. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. *Diabetes*. 1996;45:1233–1237.

5. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature*. 2000;404:787–790.

6. Kowlu RA, Kowlu V, Xiong Y, Ho YS. Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. *Free Radic Biol Med*. 2006;41:1191–1196.

7. Kanwar M, Chan PS, Kern TS, Kowlu RA. Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. *Invest Ophthalmol Vis Sci*. 2007;48:3805–3811.

8. Giacco F, Du X, Carratu A, et al. GLP-1 cleavage product reverses persistent ROS generation after transient hyperglycaemia by disrupting an ROS-generating feedback loop. *Diabetes*. 2015;64:3273–3284.

9. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. *J Clin Invest*. 2001;108:1341–1348.

10. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature*. 2001;414:813–820.

11. Korshunov SS, Skulachev VP, Starkov AA. High protonic potential activates a mechanism of production of reactive oxygen species in mitochondria. *FEBS Lett*. 1997;416:15–18.

12. da-Silva WS, Gomez-Puyou A, de Gomez-Puyou MT, et al. Mitochondrial bound hexokinase activity as a preventive antioxidant defense: steady-state ADP formation as a regulatory mechanism of membrane potential and reactive oxygen species generation in mitochondria. *J Biol Chem*. 2004;279:39846–39855.

13. Pastorino JG, Hock JB, Shulga N. Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. *Cancer Res*. 2005;65:10545–10554.

14. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature*. 1995;378:785–789.

15. Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. *Mol Cell*. 2001;7:1321–1327.

16. Dennis MD, Coleman CS, Berg A, Jefferson LS, Kimball SR. REDD1 enhances protein phosphatase 2A-mediated dephosphorylation of Akt to repress mTORC1 signaling. *Sci Signal*. 2014;7:ra68.

17. Shoshani T, Faerman A, Mett I, et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTH201, involved in apoptosis. *Mol Cell Biol*. 2002;22:2283–2293.

18. Ellisen LW, Ramsayer KD, Johannessen CM, et al. REDD1, a developmentally regulated transcriptional target of p53 and p53, links p53 to regulation of reactive oxygen species. *Mol Cell*. 2002;10:995–1005.

19. Qiao S, Dennis M, Song X, et al. A REDD1/TXNIP pro-oxidant complex regulates ATG-4B activity to control stress-induced autophagy and sustain exercise capacity. *Nat Commun*. 2015;6:7014.

20. Horak P, Crawford AR, Vadyisirassack DD, et al. Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. *Proc Natl Acad Sci U S A*. 2010;107:4675–4680.

21. Dennis MD, Kimball SR, Fort PE, Jefferson LS. Regulated development and DNA damage 1 is necessary for hyperglycemia-induced vascular endothelial growth factor expression in the retina of diabetic rodents. *J Biol Chem*. 2015;290:3865–3874.

22. Miller WP, Yang C, Mholeiscue ML, et al. Deletion of the Akt/mTORC1 repressor REDD1 prevents visual dysfunction in a rodent model of type 1 diabetes. *Diabetes*. 2018;67:110–119.

23. Brafman A, Mett I, Shafir M, et al. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. *Invest Ophthalmol Vis Sci*. 2004;45:3796–3805.

24. Nguyen QD, Schachar RA, Nduaka CI, et al. Dose-ranging evaluation of intravitreal siRNA PF-04512655 for diabetic macular edema (the DEGAS study). *Invest Ophthalmol Vis Sci*. 2012;53:7666–7674.

25. Dai W, Miller WP, Toro AL, et al. Deletion of the stress-response protein REDD1 promotes ceramide-induced retinal cell death and JNK activation. *FASEB J*. 2018;32:6885–6897.

26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods*. 2001;25:402–408.

27. Miller WP, Mholeiscue ML, Yang C, et al. The translational repressor 4E-BP1 contributes to diabetes-induced visual dysfunction. *Invest Ophthalmol Vis Sci*. 2016;57:1327–1337.

28. Tsai GY, Cui JZ, Syed H, et al. Effect of N-acetylcysteine on the early expression of inflammatory markers in the retina and plasma of diabetic rats. *Clin Exp Ophthalmol*. 2009;37:223–231.

29. Zhu Y, Zhang XL, Zhu BF, Ding YN. Effect of antioxidant N-acetylcysteine on diabetic retinopathy and expression of VEGF and ICAM-1 from retinal blood vessels of diabetic rats. *Mol Biol Rep*. 2012;39:3727–3735.

30. Du Y, Veenstra A, Palczewski K, Kern TS. Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. *Proc Natl Acad Sci U S A*. 2013;110:16586–16591.

31. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. *J Clin Invest*. 1998;102:783–791.

32. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. *Invest Ophthalmol Vis Sci*. 2005;46:2210–2218.

33. Gastinger MJ, Singh RS, Barber AJ. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. *Invest Ophthalmol Vis Sci*. 2006;47:3143–3150.

34. Seigel GM, Mitchler AL, Imperato EL. Expression of glial markers in a retinal precursor cell line. *Mol Vis*. 1996;2:2.

35. Dennis MD, McGhee NK, Jefferson LS, Kimball SR. Regulated in DNA damage and development 1 (REDD1) promotes cell survival during serum deprivation by sustaining repression of signaling through the mechanistic target of rapamycin in complex 1 (mTORC1). *Cell Signal*. 2013;25:2709–2716.

36. Aquilano K, Baldelli S, Cirillo MR. Glutathione: new roles in redox signaling for an old antioxidant. *Front Pharmacol*. 2014;5:196.

37. Sekhar RV, McKay SV, Patel SG, et al. Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. *Diabetes Care*. 2011;34:162–167.

38. Arend O, Remky A, Evans D, Stuber R, Harris A. Contrast sensitivity loss is coupled with capillary dropout in patients
39. North RV, Farrell U, Banford D, et al. Visual function in young IDDM patients over 8 years of age. A 4-year longitudinal study. Diabetes Care. 1997;20:1724-1750.

40. Della Sala S, Bertoni G, Somazzi L, Stubbe F, Wilkins AJ. Impaired contrast sensitivity in diabetic patients with and without retinopathy: a new technique for rapid assessment. Br J Ophthalmol. 1998;69:136-142.

41. Safi S, Rahimi A, Raeesi A, et al. Contrast sensitivity to spatial gratings in moderate and dim light conditions in patients with diabetes in the absence of diabetic retinopathy. BMJ Open Diabetes Res Care. 2017;5:e000408.

42. Liu C, Lu XZ, Shen MZ, et al. N-acetyl cysteine improves the diabetic cardiac function: possible role of fibrosis inhibition. BMC Cardiovascular Disorders. 2015;15:84.

43. Watson WH, Yang X, Choi YE, Jones DP, Kehrer JP. Thioredoxin and its role in toxicology. Toxicol Sci. 2004;78:3-14.

44. Junn E, Han SH, Im JY, et al. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol. 2000;164:6287-6295.

45. Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis. 2010;1:e65.

46. Reiter CE, Sandirasegarane L, Wolpert EB, et al. Characterization of insulin signaling in rat retina in vivo and ex vivo. Am J Physiol Endocrinol Metab. 2003;285:E763-E774.

47. Adams AJ, Bearse MA Jr. Retinal neuropathy precedes vasculopathy in diabetes: a function-based opportunity for early treatment intervention? Clin Exp Optom. 2012;95:256-265.

48. Han Y, Bearse MA Jr, Schneck ME, et al. Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci. 2004;45:948-954.

49. Grosche A, Hauser A, Lepper ME, et al. The proteome of native adult muller glial cells from murine retina. Mol Cell Proteomics. 2016;15:462-480.

50. Harrison WW, Bearse MA Jr, Ng JS, et al. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci. 2011;52:772-777.